Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

Inborn Errors of Immunity, Diagnostic Frameworks, and European Vaccination Protocols

Inborn Errors of Immunity (IEI)—historically termed Primary Immunodeficiency Disorders (PID)—comprise a heterogeneous spectrum of monogenic diseases impairing the development, differentiation, or function of the immune system. Early clinical recognition is essential: timely diagnosis prevents end-organ damage (e.g., bronchiectasis), allows curative hematopoietic cellular therapies, and prevents catastrophic iatrogenic complications such as fatal infections from live attenuated vaccines.

---

The Jeffrey Modell 10 Warning Signs of Primary Immunodeficiency

The Jeffrey Modell Foundation established 10 clinical warning signs to guide general pediatricians in identifying children requiring immediate immunological workup:

               THE JEFFREY MODELL 10 WARNING SIGNS OF PID

  1. >= 4 New Ear Infections (Otitis Media) within 1 Year
  2. >= 2 Serious Sinus Infections within 1 Year
  3. >= 2 Months on Antibiotics with Little or No Clinical Benefit
  4. >= 2 Pneumonias within 1 Year
  5. Failure of an Infant to Gain Weight or Grow Normally (Failure to Thrive)
  6. Recurrent, Deep Skin or Organ Abscesses (e.g., Hepatic, Perirectal)
  7. Persistent Oral Thrush or Cutaneous Fungal Infection After Age 1 Year
  8. Need for Intravenous Antibiotics to Clear Infections
  9. >= 2 Deep-Seated Infections (Septicemia, Meningitis, Osteomyelitis)
 10. A Positive Family History of Primary Immunodeficiency

---

Classification and Pathophysiology of Primary Immunodeficiencies

Primary immunodeficiencies are classified into four major functional branches based on the component of the immune system affected:

---

Detailed Molecular and Clinical Subtypes

1. B-Cell / Antibody Deficiencies

• X-Linked Agammaglobulinemia (XLA / Bruton's Disease): Caused by loss-of-function mutations in the BTK gene on chromosome Xq22, encoding Bruton tyrosine kinase. BTK is an intracellular signaling molecule essential for the transition of pro-B cells to pre-B cells in the bone marrow. As a result, B-cell development is arrested.
  • Immunological Hallmarks: Complete absence or profound reduction of mature circulating B lymphocytes (CD19+ and CD20+ B cells $<1\%–2\%$), accompanied by profound pan-hypogammaglobulinemia (undetectable or markedly low IgG, IgA, IgM, and IgE). Normal T-cell numbers (CD3+, CD4+, CD8+).
  • Clinical Presentation: Affected male infants become symptomatic around 6 to 9 months of age, coinciding with the physiological clearance of transplacentally acquired maternal IgG. They suffer recurrent, severe sinopulmonary bacterial infections (S. pneumoniae, H. influenzae), purulent conjunctivitis, skin infections, and enteroviral meningoencephalitis. On physical examination, tonsils and peripheral lymph nodes are absent or severely hypoplastic.
  • Management: Lifelong monthly intravenous immunoglobulin (IVIG) or weekly subcutaneous immunoglobulin (SCIG) replacement therapy. Live vaccines are strictly contraindicated.
• Common Variable Immunodeficiency (CVID): The most frequent clinically significant primary immunodeficiency presenting in older children, adolescents, and adults. Characterized by impaired terminal differentiation of B cells into functional antibody-secreting plasma cells.
  • Immunological Hallmarks: Normal or near-normal numbers of circulating B cells, but markedly decreased serum IgG (at least 2 SD below the age-adjusted mean) PLUS low IgA and/or IgM, combined with absent or defective antibody responses to protein (tetanus) or polysaccharide (pneumococcal) vaccines.
  • Clinical Features: Recurrent sinopulmonary infections leading to bronchiectasis; non-caseating granulomatous disease (liver, lungs); high prevalence of autoimmune cytopenias (immune thrombocytopenia [ITP], autoimmune hemolytic anemia [AIHA]); chronic enteropathy; and markedly increased risk of gastric adenocarcinoma and B-cell lymphoma.
• Selective IgA Deficiency: The most common primary immunodeficiency overall (prevalence approximately 1 in 500 to 1 in 700 in European individuals). Defined as an undetectable serum $\text{IgA} < 0.07\text{ g/L}$ with normal serum IgG and IgM levels in a child older than 4 years.
  • Clinical Relevance: Most patients are asymptomatic. Symptomatic individuals experience recurrent sinopulmonary infections, chronic giardiasis, atopic diseases, and autoimmune disorders (celiac disease, type 1 diabetes).
  • Transfusion Precautions: Anti-IgA antibodies may occur, but severe transfusion reactions are rare. With no previous reaction, standard components can be given with enhanced monitoring. After a prior transfusion reaction, consult transfusion medicine: elective transfusion may require washed red cells/platelets or IgA-deficient plasma. Do not delay life-saving transfusion if special components are unavailable; use standard components under direct monitoring with facilities to manage anaphylaxis.

2. T-Cell and Combined Immunodeficiencies

                  [Combined Immunodeficiency Spectrum]
                                   |
        +--------------------------+--------------------------+
        |                                                     |
[Severe Combined Immunodeficiency (SCID)]           [DiGeorge Syndrome (22q11.2 Deletion)]
- Complete Absence of T-Cell Immunity                - 3rd & 4th Pharyngeal Pouch Defect
- Low / Absent Neonatal TREC Screen                  - CATCH-22 Clinical Manifestations:
- Opportunistic Infections at 2-4 Months:              * Cardiac: Truncus Arteriosus, IAA, TOF
  * Pneumocystis jirovecii Pneumonia (PJP)            * Abnormal Facies (Micrognathia)
  * Cytomegalovirus (CMV), Intractable Thrush         * Thymic Hypoplasia (Low T Cells)
- Fatal in Infancy Without HSCT                       * Cleft Palate / Hypernasal Speech
- Irradiated, Leukodepleted Blood Only                * Hypocalcemia (Parathyroid Aplasia)
- STRICT BAN ON ALL LIVE VACCINES                     * Neonatal Tetany / Seizures

• Severe Combined Immunodeficiency (SCID): A pediatric medical emergency characterized by absent or non-functional T lymphocytes with variable absence of B and NK cells (e.g., $T^- B^+ NK^-$ due to X-linked common gamma chain mutation IL2RG; $T^- B^- NK^-$ due to Adenosine Deaminase [ADA] deficiency; $T^- B^- NK^+$ due to RAG1/RAG2 mutations).
  • Newborn Screening: Quantifies T-cell receptor excision circles (TRECs) via real-time PCR on newborn dried blood spots. TRECs are stable circular DNA fragments produced during normal TCR rearrangement in the thymus; low or absent TRECs identifies SCID presymptomatically at birth.
  • Clinical Course: Infants present within the first 2 to 4 months of life with severe failure to thrive, chronic intractable diarrhea, persistent oral candidiasis, and life-threatening opportunistic infections, especially Pneumocystis jirovecii pneumonia (PJP) and Cytomegalovirus (CMV).
  • Mandatory Precautions:
    1. Strict contraindication of all live vaccines (administration of rotavirus vaccine causes persistent fatal diarrhea; BCG causes lethal disseminated BCG-osis).
    2. All blood products must be leukodepleted, irradiated (to prevent fatal Transfusion-Associated Graft-versus-Host Disease [TA-GvHD]), and CMV-seronegative.
    3. Co-trimoxazole (trimethoprim-sulfamethoxazole) prophylaxis for PJP and regular IVIG while immunodeficient; reassess their continuation after definitive therapy and immune reconstitution.
    4. Definitive curative therapy: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) or autologous gene therapy.
• DiGeorge Syndrome (22q11.2 Deletion Syndrome): Disruption of the embryonic development of the third and fourth pharyngeal pouches caused by a heterozygous microdeletion on chromosome 22q11.2. Remembered by the mnemonic CATCH-22:
  • C - Cardiac defects: Conotruncal anomalies, including interrupted aortic arch (type B), truncus arteriosus, tetralogy of Fallot, and ventricular septal defect (VSD).
  • A - Abnormal facies: Hypertelorism, micrognathia, low-set malformed ears, short philtrum, and prominent nasal root with bulbous tip.
  • T - Thymic hypoplasia / aplasia: Defective T-cell maturation. Most children have 'partial DiGeorge' with mild-to-moderate T-cell lymphopenia that improves with age; fewer than 1% have 'complete DiGeorge' (athymic, presenting with a SCID phenotype requiring cultured thymus transplantation).
  • C - Cleft palate: Submucous cleft palate, bifid uvula, and velopharyngeal insufficiency causing hypernasal speech.
  • H - Hypocalcemia: Secondary to parathyroid gland hypoplasia, presenting in the neonatal period with hypocalcemic tetany, tremors, carpopedal spasm, or seizures.

3. Phagocytic Disorders

• Chronic Granulomatous Disease (CGD): Impairment of the phagocyte respiratory (oxidative) burst caused by mutations in the multicomponent NADPH oxidase enzyme complex (most commonly X-linked recessive mutations in CYBB encoding gp91phox [~70%], followed by autosomal recessive mutations in NCF1 [p47phox]). Phagocytes ingest bacteria normally but cannot synthesize reactive oxygen species (superoxide anion, hydrogen peroxide, hypochlorous acid) to kill internalized microbes.
  • The Catalase-Positive Vulnerability: Microorganisms produce small amounts of endogenous hydrogen peroxide as metabolic by-products. Most bacteria lack catalase, allowing the neutrophil to utilize the microbe's own hydrogen peroxide to effect killing. However, catalase-positive microorganisms produce the enzyme catalase, which degrades hydrogen peroxide ($2\text{H}_2\text{O}_2 \rightarrow 2\text{H}_2\text{O} + \text{O}_2$). Deprived of both host and microbial peroxides, CGD neutrophils cannot destroy these pathogens.
  • The Five Classic Pathogens: Staphylococcus aureus, Aspergillus species, Serratia marcescens, Burkholderia cepacia complex, and Nocardia species (alongside Salmonella).
  • Clinical Hallmark: Recurrent suppurative lymphadenitis, hepatic and splenic abscesses, osteomyelitis (Serratia), pulmonary fungal granulomas, and chronic inflammatory granuloma formation obstructing the gastric outlet or urinary tract.
  • Diagnostic Test: Dihydrorhodamine 123 (DHR) flow cytometry assay. Neutrophils are stimulated ex vivo; oxidation of non-fluorescent DHR to brightly fluorescent rhodamine by intracellular hydrogen peroxide is quantified. CGD neutrophils exhibit complete failure of fluorescence shift. (Replaces the obsolete nitroblue tetrazolium / NBT test).
  • Management: Lifelong daily antibacterial prophylaxis with Co-trimoxazole, daily antifungal prophylaxis with Itraconazole, and subcutaneous Recombinant Interferon-gamma (IFN-$\gamma$); definitive cure achieved via HSCT.
• Leukocyte Adhesion Deficiency Type 1 (LAD-1): Autosomal recessive defect in the ITGB2 gene encoding the CD18 beta-2 integrin subunit. Neutrophils cannot adhere to endothelial ICAM-1 and fail to extravasate from the bloodstream into infected peripheral tissues.
  • Clinical Triad: Delayed separation of the umbilical cord ($>3\text{ to }4$ weeks of life); severe necrotic, ulcerating skin and mucous membrane infections that conspicuously lack pus formation (cold abscesses); and extreme, persistent peripheral leukocytosis / neutrophilia ($20,000\text{ to }100,000 /\mu\text{L}$) even when clinically uninfected.

4. Complement Deficiencies

• Terminal Complement Deficiencies (C5, C6, C7, C8, C9 / Membrane Attack Complex [MAC]): Failure to assemble the lytic pore complex ($C5b\text{–}9$). Clinically characterized by striking, recurrent, invasive meningococcal disease caused by Neisseria meningitidis, frequently involving uncommon serogroups (W-135, Y, X). Screened via the CH50 (total hemolytic complement) assay, which is zero or markedly depressed.
• Hereditary Angioedema (HAE): Autosomal dominant deficiency (Type I) or dysfunction (Type II) of C1 Esterase Inhibitor (C1-INH). Unregulated kallikrein activation drives excessive production of bradykinin. Presents with recurrent, self-limiting episodes of non-pruritic, non-pitting subcutaneous angioedema, agonizing abdominal pain (bowel edema), and life-threatening laryngeal edema. Urticaria and pruritus are completely absent. Investigate suspected HAE with C1-INH function, C1-INH antigen level and serum C4; C4 alone is insufficient. Acute treatment utilizes C1-INH concentrate or Icatibant (bradykinin B2 receptor antagonist).

---

Vaccination Protocols and Contraindicated Live Vaccines

Live Attenuated versus Inactivated Vaccines

Absolute Contraindications to Live Vaccines in Children

Live vaccines are contraindicated during significant immunosuppression; reintroduction requires specialist assessment and the applicable national guidance. Important situations include:

1. Severe T-cell / Combined Immunodeficiencies: SCID, complete DiGeorge syndrome, severe ataxia-telangiectasia, Wiskott-Aldrich syndrome.
2. Malignancy and Active Chemotherapy: Leukemia, lymphoma, or solid tumors undergoing immunosuppressive cytotoxic therapy, and for at least 6 months following cessation of chemotherapy.
3. Systemic Corticosteroids: Apply the national rule. CDC uses prednisolone-equivalent ≥2 mg/kg/day or ≥20 mg/day if >10 kg for ≥14 days, followed by at least 1 month before live vaccines. UK Green Book excludes live vaccines for 3 months after >40 mg/day (2 mg/kg/day if <20 kg) for >1 week, or >20 mg/day (1 mg/kg/day if <20 kg) for >14 days.
4. Biological Immunosuppressive Therapy: Anti-TNF agents (infliximab, adalimumab) and B-cell depleting therapies (rituximab; defer live vaccines for 6–12 months).
5. Post-Hematopoietic Stem Cell Transplantation (HSCT): Defer live vaccines for at least 24 months post-transplant, and only if the child is free of active Graft-versus-Host Disease (GvHD) and off all systemic immunosuppressive medications.

European Routine Childhood Immunisation Architecture

European programmes share core vaccines, but dose timing and products follow each country's current schedule and birth-cohort rules; consult the national programme or ECDC Vaccine Scheduler:

• Hexavalent Vaccine (DTaP-IPV-Hib-HepB): Diphtheria, Tetanus, acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae type b capsular conjugate, and Hepatitis B surface antigen. Delivered according to standard European 2+1 schedules (2, 4, and 11–12 months) or 3+1 schedules (2, 3, 4, and 11–12 months).
• Pneumococcal Conjugate Vaccines (PCV13 / PCV15 / PCV20): These CRM197-conjugated products protect against invasive pneumococcal disease. Follow the national and product-specific schedule: EMA's Prevenar 20 infant regimen has three primary doses from 6 weeks of age plus a booster at 11–15 months; a three-dose total series is not interchangeable across all products.
• Meningococcal Vaccines: Recombinant protein MenB vaccine and quadrivalent conjugate MenACWY vaccine.
• Measles-Containing Vaccine: Give two routine doses at nationally specified ages. Germany recommends MMR at 11 and 15 months; England offers MMRV at 12 and 18 months for eligible birth cohorts from 2026. Catch-up and earlier outbreak/travel doses follow national guidance.
• Human Papillomavirus (HPV) Vaccine: Recombinant L1 virus-like particle vaccines prevent HPV-associated cancers and genital warts. Vaccinate girls and boys before exposure using the national schedule: programmes may use one or two routine doses. England uses one dose at 12–13 years, with three doses for immunosuppressed or HIV-positive recipients.